glp 1 trump administration Trump's Plan to Expand Access to Weight-Loss Drugs Just Hit a Major Roadblock 💊WEIGHT-LOSS DRUG DEBATE: The Trump

Peer review Peer review information Nature Reviews Gastroenterology & Hepatology thanks Alberto Camineo, Sunny Hei Wong and Bahtiyar Yilmaz for their contribution to the peer review of this work

This IV program focuses on nutrients involved in cellular energy production and mitochondrial function

However, such methods have been either unpractical and/or unsuccessful

IV infusions deliver B12 intravenously through a catheter placed in a vein

Expert Opinion on Biological Therapy, 12 (1), 3751

A 48-week Phase 2 trial reported in The Lancet in 2025 showed mean weight reduction ranging from approximately 9% at the lowest dose to 20% at the highest dose, compared with 0.4% on placebo